Universidad Autonoma de Chile Researchers Provide New Study Findings on Gastric Cancer (Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival).

Researchers at the Universidad Autonoma de Chile conducted a study on gastric cancer, focusing on the use of a combination of Maraviroc and cisplatin to inhibit tumor growth and improve survival rates in mice. The study found that the combination treatment reduced cell viability, inhibited tumor formation, and improved survival rates in mice treated with cisplatin. The researchers concluded that the Maraviroc/cisplatin combination could be a potential complementary therapy for gastric cancer. [Extracted from the article]